肾移植前免疫诱导治疗的进展

赵海涛; 刘致中

肾移植前免疫诱导治疗的进展

赵海涛,
刘致中^,

- 内蒙古医科大学第三附属医院, 内蒙古包钢医院泌尿外科(内蒙古包头, 014010)

详细信息

通讯作者: 刘致中,E-mail:zhtdld@yahoo.cn

中图分类号: R699.2

收稿日期: 2012-12-25

Progression of induction therapy before kidney transplantation

ZHAO Haitao,
LIU Zhizhong^,

- Department of Urology, Third Affiliated Hospital of Inner Mongolia Medical University, Baotou, Inner Mongolia, 014010, China

More Information

Corresponding author: LIU Zhizhong, E-mail: zhtdld@yahoo.cn

Received Date: 25 December 2012

摘要

摘要: 为晚期肾病患者实施肾移植手术已成为尿毒症患者的最佳治疗方案，可手术后的排异反应始终困扰着医生和患者。术后使用免疫抑制剂是肾移植的常规治疗方案，但人们发现围手术期使用免疫抑制剂进行免疫诱导可降低排异反应的发生，减少术后免疫抑制剂的使用剂量，正逐步成为肾移植免疫学的研究热点。本文为此作一综述。
- 肾移植 /
- 免疫诱导
Abstract: Renal transplantation has became the best treatment protocols for the end-stage renal disease pations. But the rejection always puzzles doctors and pations after the operations. Immunosuppression is the conventional therapy after transplantation, but many research discovery induction therapy before operation can decrease rejection and dose of immunosuppressive agent. So induction therapy now is becoming warm spot of kidney transplantation immunity.
- kidney transplant /
- immunosuppression induction

HTML全文

参考文献(50)

[1]	Golshayan D, Pascual M0. Tolerance-inducing immunosuppressive atrategies in clinical transplantation:an overview[J]. Drugs, 2008, 68(15):2113-2130.
[2]	Holowiecki J. Indications for hemalopoietic stem cell transplantation[J]. Pol Arch Med Wewn, 2008,118(11):658-663.
[3]	Barbari A, Stephan A, Masri M A. Donor specific transfusion in kidney tansplantation:effect of different immunosuppressive protocols on graft outcome[J].Transplant Prose, 2001, 33(5):2782-2785.
[4]	Alexander J W, Light J A, Donaldson L A, et al. Evaluation of pre and posttransplantation donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplantantrecipients. Cooperative Ckinical Trials in Transplantation Research Group[J]. Transplantation, 1999, 68(8):1117-1124.
[5]	Taylor P A, Panoskaltsis-Mortari A, Swedin J M, et al. L-Selection(hi) but not the L-Selection(lo) CD4+25+T-Regulation[J]. Blood, 2004, 104(12):3804-3812.
[6]	Spitzer T R, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease:the induction of allograft tolerance through mixed lymphohematopoieticchimeriam[J]. Transplantation, 1999, 68(4):480-484.
[7]	Milan M T, Shizuru J A, Hoffmann P, et al. Mixedchimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation[J].Transplantation, 2002, 73(9):1386-1391.
[8]	Trivedi H L,Vaniker A V, Vakil J M, et al. Astralegy to achieve donor-specific hyporesponsivencess in cadaver renal allograft recipients by donor haematopoietic stem cell transplantation into the thymus and periphery[J]. Nephrol Dial Transplant, 2004, 19(9):2374-2377.
[9]	Ricordi C, Ildstad S T, Demetris A J. Donor dendritic cell repopulation in recipients after rat-to-mouse bone-marrow transplantation[J]. Lancet, 1992, 339(8809):1610-1611.
[10]	Levy A E, Alexander J W, Babcock G F. A strategy for generating consistent long-term donor-specific tolerance to solid organ allografts[J]. TransplImmunol, 1997, 5(2):83-88.
[11]	Starzl T E, Demetris A J, Murase N, et al. Cell migration, chimerism, and graft acceptance[J]. Lancet, 1992, 339(8809):1579-1582.
[12]	Freeman G J, Borriello F, Hodes R J, et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production[J]. J Exp Med, 1993, 178(6):2185-2192.
[13]	Gur H, Krauthgamer R, Berrebi A, et al. Tolerance induction by megadose hematopoietic progenitor cells:expansion of veto cells by short-term culture of purified human CD34(+) cells[J]. Blood, 2002, 99(11):4174-4181.
[14]	Mc Daniel D O, Naftilan J, Hulvey K, et al. Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow[J].Transplantation, 1994, 57(6):852-856.
[15]	Crop M J, Baan C C, Korevaar S S, Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients[J]. Transplantation, 2009, 87(6):896-906.
[16]	何琼,朱晓东,陈红. 骨髓间充质干细胞移植在大鼠急性肝损伤组织中的定植能力[J]. 中国组织工程研究与临床康复,2009,13(23):4437-4441.
[17]	Figliuzzi M, Cornolti R, Perico N, et al. Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats[J].Transplant Proc, 2009, 41(5):1797-800.
[18]	王共先,符彦基. 骨髓间充质干细胞移植修复肾损伤[J]. 中国组织工程研究与临床康复,2008,12(38):7422-7426.
[19]	Shi H, Patschan D, Dietz G P, et al. Glial cell line-derived neurotrophic growth factor increases motility and survival of cultured mesenchymal stem cells and ameliorates acute kidney injury[J]. Am J Physiol Renal Physiol, 2008, 294(1):F229-35.
[20]	Zhuo W, Liao L, Xu T, et al. Mesenchymal stem cells ameliorate ischemia-reperfusion-induced renal dysfunction by improving the antioxidant/oxidant balance in the ischemic kidney[J]. Urol Int, 2011, 86(2):191-196.
[21]	Le Blanc K, Rasmusson I, Gǒtherstrǒm C, et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes[J]. Scand J Immunol, 2004, 60(3):307-315.
[22]	Sheng Sun D, Iwagaki H, Ozaki M, et al. Prolonged survival of donor-specific rat intestinal allograft by administration of bone-marrow-derived immature dendritic cells[J]. TransplImmunol, 2005, 14(1):17-20.
[23]	赵鸿,王翔,张元芳,等. 未成熟树突状细胞联合骨髓移植诱导肾移植大鼠免疫耐受及其机制[J]. 复旦学报(医学版), 2005, 32(1):63-65.
[24]	Peddi V R, Bryant M, Roy-Chaudhury P, et al. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients[J]. Transplantation, 2002, 73(9):1514-1518.
[25]	Cai J, Terasaki P I, et al. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation:an analysis of United Network for Organ Sharing registry data[J]. Transplantation, 2010, 90(12):1511-1515.
[26]	张玉石,李汉忠. 肾移植免疫诱导治疗[J]. 国外医学移植与血液净化分册, 2004, 2(1):18-21.
[27]	Thibaudin D, Alamartine E, de Filippis J P, et al. Advantage of antithymocyte globulin induction in sensitized kidney recipients:a randomized prospective study comparing induction with and without antithymocyte globulin[J]. Nephrol Dial Transplant, 1998, 13(3):711-5.
[28]	Ault B H, Honaker M R, Osama Gaber A, et al. PediatrNephrol.Short-term outcomes of Thymoglobulin induction in pediatric renal transplant recipients[J]. 2002, 17(10):815-818.
[29]	Colovai A I, Vasilescu E R, Foca-Rodi A, et al. Acute and hyperacutehumoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies[J]. Hum Immunol, 2005, 66(5):501-512.
[30]	施国海,王祥慧,徐达. 小剂量兔抗人胸腺细胞免疫球蛋白和噻尼哌在肾移植诱导治疗中的应用效果[J]. 中华泌尿外科杂志, 2006, 27(12):821-824.
[31]	Kaden J, May G, Müller P, et al. Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival[J]. Transplant Proc, 1995, 27(1):1060-1061.
[32]	杨顺良,谭建明,吴为真,等. 致敏肾移植受者术前单次大剂量抗胸腺细胞球蛋白诱导治疗的价值[J]. 中华泌尿外科杂志, 2004, 25(11):746-749.
[33]	Varghese Z, Abudher M N, Fernando O N, et al. Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients[J]. Transplant Proc, 2001, 33(3):2251-2253.
[34]	Abudher M N, Moorhead J F, Fernando O N, et al. Preoperative ATG bolus treatment increase CsA sensitivity of peripheral blood lymphocytes (PBLS) in renal transplant patients[J]. Transplant Proc, 1999, 31(8):3361-3364.
[35]	Nikolovski M, KotsevIu, Dimitrov S, et al. The role of polyclonal anti-T-lymphocyte antibodies (ATG) in the kidney transplantation[J]. Khirurgiia(Sofiia), 2004, 60(4-5):42-45.
[36]	Henell K R, Norman D J. Monitoring OKT3 treatment:pharmacodynamic and pharmacokinetic measures[J]. Transplant Proc, 1993, 25(2 Suppl 1):83-85.
[37]	Benfield M R, Tejani A, Harmon W E, et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation[J]. Pediatr Transplant, 2005, 9(3):282-292.
[38]	Flechner S M, Goldfarb D A, Fairchild R, et al. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants[J]. Transplantation, 2000, 69(11):2374-2381.
[39]	Sheashaa H A, Bakr M A, Ismail A M, et al. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation:a five-year prospective randomized study[J]. Am J Nephrol, 2005, 25(3):221-5.
[40]	Ekberg H, Bǎckman L, TufvesonG, et al. Daclizumab prevents acute rejection and improves patient survival post transplantation:1 year pooled analysis[J]. Transpl Int, 2000, 13(2):151-159.
[41]	Bumgardner G L, Hardie I, Johnson R W, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation[J]. Transplantation, 2001, 72(5):839-845.
[42]	王长希,邱江,陈立中,等. 噻尼哌在肾移植免疫诱导治疗中的作用[J]. 中山大学学报(医学科学版), 2004, 25:273-275.
[43]	Sheashaa H A, Bakr M A, Rashad R H, et al. Ten-year follow-up of basiliximab induction therapy for live-donor kidney transplant:a prospective randomized controlled study[J]. ExpClin Transplant, 2011, 9(4):247-251.
[44]	Kim Y, Park K H, Chung B H, et al. Pretransplant IFN-γ ELISPOT assay as a potential screening test to select immunosuppression protocols for patients receiving basiliximab induction therapy[J]. Transl Res, 2012, 160(3):230-236.
[45]	平季根,严春寅,吕金星. CTLA4-Ig腺病毒基因局部转染诱导大鼠肾移植免疫耐受[J]. 实验动物与比较医学, 2007, 27(1):45-47.
[46]	He W, Fang Z, Wang F, et al. Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice[J]. Transplantation, 2009, 88(6):782-790.
[47]	李成文,王,高燕,等. Galectin-9基因转染诱导大鼠肾移植免疫耐受的实验研究[J]. 现代预防医学, 2011, 38(5):971-974.
[48]	徐光勇,张唯力,张荣贵,等. FasL基因转染诱导大鼠肾移植免疫耐受的实验研究[J]. 重庆医科大学学报, 2009, 34(9):1162-1165.
[49]	Ke B, Shen X D, Buelow R, et al. Heme oxygenase-1 gene transfer prevents CD95/FasL-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway[J]. Transplant Proc, 2002, 34(5):1465-1466.
[50]	平季根,温瑞改,候建全,等. 腺病毒介导的hCTLA4-Ig和FasL基因转移诱导大鼠同种异体肾移植长期存活的作用[J]. 中华实验外科杂志, 2009, 26(10):1269-1271.